,
6 min read
Software is increasingly shaping clinical decisions, triaging symptoms, identifying risk patterns, guiding therapy selection, and monitoring patients between visits. That shift has created tremendous opportunity, but it has also changed the meaning of “Regulatory readiness.” Unlike hardware-led devices, software evolves rapidly, depends on data quality, and may behave differently as it scales across clinical settings.
A resilient SaMD Regulatory strategy is therefore less about producing a single “perfect” submission and more about designing a lifecycle approach that can withstand iterative releases, multi-market scrutiny, and rising expectations around cybersecurity, privacy, and real-world performance.
When executed well, a Regulatory strategy becomes a blueprint for how Regulatory decisions get made. Linking intended use, clinical evidence, risk controls, and change governance into a coherent Regulatory plan becomes essential for sustainable market access.
Further described in the blog are strategies that help companies navigate complex Regulatory pathways.
Start with the clinical “why” and build the Regulatory narrative around it
High-performing teams begin by articulating what the software changes in healthcare. Regulators evaluate that narrative, how the software influences outcomes, whether humans remain in the loop, and how foreseeable hazards are prevented.
This is why the first strategic move is to define the intended use with sufficient precision to be testable and auditable, while still communicating real clinical value. If your claims are overly broad (“supports diagnosis across conditions”), classification becomes unstable, and evidence becomes diffuse. If they are too narrow, you risk locking the product into a scope that cannot scale. A strong strategy frames the claim so it can be validated in the real world and defended through change.
The experts at Freyr Solutions can help you define the intended use that aligns with the clinical claims of your software. We have specialised tools that can map the clinical indications to the Regulatory requirements based on your software’s risk classification.
Classify early using a risk logic that translates across markets
Classification is not a paperwork step; it is the decision that shapes evidence depth, documentation complexity, post-market obligations, and the level of conservatism required in your change-control thresholds. The most defensible classification rationales combine two (2) lenses:
- Clinical context and severity: What condition is involved, and what is the harm if the software goes wrong?
- Decision influence: Does the output inform care, or does it drive/replace clinical judgment?
This is where IMDRF SaMD frameworks are beneficial: they offer a structured, globally intelligible way of describing clinical impact and the software’s role in decision-making. Even when local rules vary, IMDRF-style reasoning makes your classification logic easier to defend across geographies and over time.
Classification should also be treated as a living rationale. New features, broader indications, additional data sources, and algorithm updates can shift risk contribution, especially for AI-enabled systems, so teams that revisit classification assumptions as part of governance tend to avoid late-stage surprises.
The clinical and Regulatory experts at Freyr help guide you through these global Regulatory requirements and additional IMDRF-specific SaMD requirements to ensure accurate risk classification for your software, which further drives the company's global Regulatory strategy.
Sequence markets to reduce rework and increase evidence reuse
Many SaMD teams try to run US and EU workstreams in parallel, then discover that differing evidence expectations and documentation conventions create duplication and inconsistency. A stronger approach starts with market sequencing that optimizes three (3) realities: evidence portability, pathway predictability, and lifecycle burden.
In the US, FDA SaMD expectations, captured in the FDA’s Software as a Medical Device (SaMD) overview, shape how teams interpret FDA SaMD guidance on validation, lifecycle controls, and changes, especially as digital health policy continues to mature across product categories. The most durable strategies explicitly connect intended use and risk classification to a validation plan that remains coherent through iterations.
In Europe, EU MDR compliance is shaped not only by classification but also by sustained obligations for clinical evaluation, PMS/PMCF where relevant, and depth of technical documentation. Several MDCG documents, including the MDCG guidance on the qualification and classification of software, are widely regarded as a core interpretive reference for software under MDR/IVDR, and they can help teams avoid misalignment between the intended purpose and the class justification.
Design evidence as a lifecycle asset, not a submission artifact
For SaMD products, evidence should be treated as an evolving asset that remains valid through updates, not a one-time artifact produced for launch. A modern evidence plan connects three (3) layers into One (1) continuous story:
- Analytical validation: Does it compute correctly and reliably under expected conditions?
- Clinical validation: Does it demonstrate clinically meaningful performance in the intended population and setting?
- Usability and human factors: Can intended users apply outputs safely and as intended within real workflows?
When software is AI-enabled, the bar rises further. Teams need to demonstrate governance for dataset relevance, bias, and generalizability risks; drift monitoring; and controls for model evolution. This is where disciplined SaMD Regulatory processes pay off. If you can demonstrate that evidence is maintained through governance, rather than rebuilt ad hoc, Regulatory review becomes more predictable, and lifecycle operations become far less brittle.
Dedicated AI and Software teams at Freyr Solutions can help review your validation documentation to ensure the evidence generated by your software aligns with the intended clinical use and supports smooth Regulatory approvals.
Build change control and quality practices for software reality
Security patches, performance improvements, UI refinements, model updates, and new integrations are standard for a SaMD product. A credible SaMD Regulatory strategy anticipates change and defines how changes are assessed for impact on intended use, risk controls, and validation scope.
This is also where software as a medical device guidance becomes operational, not theoretical. Rather than relying on generic checklists, high-maturity teams standardize a repeatable change-impact logic. What changed, why it changed, how it affects clinical performance or risk, what new evidence is required, and how traceability is maintained from requirements through verification and validation.
A strategy that treats change control as the mechanism for sustaining trust, internally and externally, tends to scale better across geographies and across product generations.
Account for AI-era expectations, including the EU AI Act, without duplicating systems
AI-enabled software is driving increasing expectations for transparency, oversight, and accountability. For EU-facing products, the EU AI Act adds a governance layer that intersects with MDR obligations; the final legal text on EUR-Lex provides the baseline framing for how high-risk AI systems are expected to be managed.
The most future-ready approaches do not create a parallel “AI compliance” universe. Instead, they integrate AI governance into the medical device lifecycle. Risk management that accounts for model uncertainty, documentation that ties model behaviour to clinical claims, and post-market monitoring that can detect drift or degradation in real-world settings.
Closing perspective
Developing a Regulatory strategy for SaMD is ultimately an exercise in building durable trust: trust that the software does what it claims, trust that risk is understood and controlled, and trust that change is managed responsibly. When your SaMD Regulatory strategy is anchored in risk-aware classification, evidence durability, and lifecycle governance, and when it anticipates evolving regimes such as EU MDR compliance and the EU AI Act, you create a strategy that supports both approval and long-term scalability.
In practice, teams that treat Regulatory strategy as a lifecycle discipline, linking classification logic, evidence durability, and change governance, tend to align more consistently with expectations outlined in the Comprehensive Guide to Software as a Medical Device (SaMD) Compliance.
Contact Freyr Solutions to discuss your SaMD Regulatory strategy and discover how Freyr can streamline your global registrations.
